Objective:To systematically integrate the best available evidence on non-pharmacological management of functional gastrointestinal symptoms (FGIDs) in patients with inflammatory bowel disease (IBD), providing evidence-based support for clinical practice.Methods:Evidence related to non-pharmacological management of FGIDs in IBD patients, including guidelines, clinical decision documents, evidence summaries, expert consensus statements, and systematic reviews, was systematically retrieved from domestic and international professional websites and databases. The search period covered February 27, 2016 to February 27, 2025. Literature was screened and appraised for quality.Results:A total of 15 studies were included. A total of 32 items of evidence were summarized across 10 aspects: multidisciplinary management, screening, assessment, dietary management, exercise management, psychological management, skin care, traditional Chinese medicine interventions, physical interventions, and health education and follow-up.Conclusions:The summarized best evidence for non-pharmacological management of FGIDs in IBD patients provides scientific and systematic guidance for healthcare professionals, helping them better identify and manage FGIDs in this population.

Saponins associated with Panax notoginseng (P. notoginseng) demonstrate significant therapeutic efficacy across multiple diseases. However, certain high-yield saponins face limited clinical applications due to their reduced pharmacological efficacy. This study synthesized and evaluated 36 saponin-1,2,3-triazole derivatives of ginsenosides Rg1/Rb1 and notoginsenoside R1 for anti-adipogenesis activity in vitro. The research revealed that the ginsenosides Rg1-1,2,3-triazole derivative a17 demonstrates superior adipogenesis inhibitory effects. Structure-activity relationships (SARs) analysis indicates that incorporating an amidyl-substituted 1,2,3-triazole into the saponin side chain via Click reaction enhances anti-adipogenesis activity. Additionally, several other derivatives exhibit general adipogenesis inhibition. Compound a17 demonstrated enhanced potency compared to the parent ginsenoside Rg1. Mechanistic investigations revealed that a17 exhibits dose-dependent inhibition of adipogenesis in vitro, accompanied by decreased expression of preadipocytes. Peroxisome proliferator-activated receptor γ (PPARγ), fatty acid synthase (FAS), and fatty acid binding protein 4 (FABP4) adipogenesis regulators. These findings establish the ginsenoside Rg1-1,2,3-triazole derivative a17 as a promising adipocyte differentiation inhibitor and potential therapeutic agent for obesity and associated metabolic disorders. This research provides a foundation for developing effective therapeutic approaches for various metabolic syndromes.
Adipogenesis/drug effects* ; Triazoles/chemical synthesis* ; Ginsenosides/chemical synthesis* ; Saponins/chemical synthesis* ; Animals ; Mice ; Structure-Activity Relationship ; PPAR gamma/genetics* ; 3T3-L1 Cells ; Adipocytes/metabolism* ; Panax notoginseng/chemistry* ; Drug Design ; Molecular Structure ; Humans ; Cell Differentiation/drug effects* ; Fatty Acid-Binding Proteins/genetics*

Objective:To systematically integrate the best available evidence on non-pharmacological management of functional gastrointestinal symptoms (FGIDs) in patients with inflammatory bowel disease (IBD), providing evidence-based support for clinical practice.Methods:Evidence related to non-pharmacological management of FGIDs in IBD patients, including guidelines, clinical decision documents, evidence summaries, expert consensus statements, and systematic reviews, was systematically retrieved from domestic and international professional websites and databases. The search period covered February 27, 2016 to February 27, 2025. Literature was screened and appraised for quality.Results:A total of 15 studies were included. A total of 32 items of evidence were summarized across 10 aspects: multidisciplinary management, screening, assessment, dietary management, exercise management, psychological management, skin care, traditional Chinese medicine interventions, physical interventions, and health education and follow-up.Conclusions:The summarized best evidence for non-pharmacological management of FGIDs in IBD patients provides scientific and systematic guidance for healthcare professionals, helping them better identify and manage FGIDs in this population.

Objective Analyzing the construction process and application of health appropriate technology database in Zhejiang province and proposing related considerations and recommendations for the database construction.Methods To design and construct the technology database system,and using excel software to calculate statistic data.Results Established a health appropriate technology database,which contains 826 technologies that can be selected and promoted by the demonstration bases in the whole province.Conclusions The establishment of the technology database increased the efficiency of health appropriate technology transformation at the provincial level,and also provided a reference for the national-wide generalizing of health appropriate technology.

A study of the quality assurance system building made at the training bases in Zhejiang since 2011 found the following.Five management systems on training quality have been established, covering basic clinical conditions, training management, faculty management and training, training assessment,and training incentives.PDCA is called into play for continuous improvement and perfection to develop a training quality management system of local features and continuous improvement.